Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279045 · ClinicalTrials.gov registry record · Phase 3
Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 4,426
- Enrollment target
NCT00279045 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 4,426 participants.
The verdict
NCT00279045, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 4,426 participants
- Enrollment target
Study Summary
The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.
Interventions
- DRUG Rosiglitazone
- DRUG metformin
- DRUG glyburide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,426 participants |
| Start Date | 2000-01-03 |
| Est. Completion | 2006-06-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279045
The ClinicalTrials.gov registry entry for NCT00279045 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 4,426 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Rosiglitazone is the first listed.
NCT00279045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00279045 about?
NCT00279045 is a clinical study titled "Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide". The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.
What is the current status of trial NCT00279045?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 4,426 participants. The study started on 2000-01-03. Estimated completion is 2006-06-19.
What interventions are being tested in trial NCT00279045?
The interventions under investigation include: Rosiglitazone (DRUG), metformin (DRUG), glyburide (DRUG).
Who is sponsoring clinical trial NCT00279045?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.